Nektar Therapeutics

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1990-01-01

Employees: 137

Market Cap: $230M

Website: http://www.nektar.com

Introduction: Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and autoimmune diseases. The company was founded in 1990 and is headquartered in San Francisco, CA.

Clinical Trials

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)

Phase 2

Recruiting

Conditions: Alopecia Areata

Interventions: Drug: Rezpegaldesleukin
Drug: Placebo

First Posted Date: 2024-04-01

Last Posted Date: 2025-01-10

Lead Sponsor: Nektar Therapeutics

Target Recruit Count: 84

Registration Number: NCT06340360

Locations: 🇵🇱
Nektar Investigative Site, Sosnowiec, Śląskie, Poland

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis

Phase 2

Recruiting

Conditions: Moderate to Severe Atopic Dermatitis

Interventions: Drug: Placebo
Drug: Rezpegaldesleukin

First Posted Date: 2023-11-18

Last Posted Date: 2024-12-11

Lead Sponsor: Nektar Therapeutics

Target Recruit Count: 396

Registration Number: NCT06136741

Locations: 🇪🇸
Nektar Investigative Site, Zaragoza, Spain
🇭🇷
Nektar Investigative Site 5701, Zagreb, Grad Zagreb, Croatia
🇭🇷
Nektar Investigative Site 5703, Zagreb, Grad Zagreb, Croatia

and more 1 locations

NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma

Phase 2

Recruiting

Conditions: Non-Hodgkin Lymphoma
Relapsed/Refractory Diffuse Large B-cell Lymphoma

Interventions: Drug: NKTR-255 at 1.5 µg/kg
Drug: NKTR-255 at 3.0 μg/kg
Other: Placebo Comparator
Drug: NKTR-255 at 3.0/6.0 μg/kg

First Posted Date: 2022-12-23

Last Posted Date: 2024-01-09

Lead Sponsor: Nektar Therapeutics

Target Recruit Count: 400

Registration Number: NCT05664217

Locations: 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
Allegheny Health Network, Pittsburgh, Pennsylvania, United States
🇺🇸
University of Maryland, Baltimore, Maryland, United States

and more 22 locations

A Phase I Study of LY3471851 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3471851
Drug: Placebo
Drug: Levocetirizine

First Posted Date: 2022-10-04

Last Posted Date: 2023-11-18

Lead Sponsor: Nektar Therapeutics

Target Recruit Count: 41

Registration Number: NCT05565729

Locations: 🇺🇸
Covance Dallas, Dallas, Texas, United States

A Single-Dose Study of LY3471851 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3471851

First Posted Date: 2021-08-10

Last Posted Date: 2023-11-18

Lead Sponsor: Nektar Therapeutics

Target Recruit Count: 71

Registration Number: NCT04998487

Locations: 🇺🇸
LabCorp CRU, Inc., Daytona Beach, Florida, United States

BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)

Phase 2

Terminated

Conditions: Metastatic Head and Neck Cancer
Recurrent Head and Neck Cancer

Interventions: Drug: Bempegaldesleukin
Drug: Pembrolizumab

First Posted Date: 2021-07-21

Last Posted Date: 2023-01-12

Lead Sponsor: Nektar Therapeutics

Target Recruit Count: 1

Registration Number: NCT04969861

Locations: 🇦🇹
Universitätsklinikum Salzburg, Landeskrankenhaus,, Salzburg, Salzburg Bundesland, Austria
🇬🇷
Attikon University General Hospital, Athens, Attiki, Greece
🇺🇸
Nebraska Methodist Hospital, Omaha, Nebraska, United States

and more 1 locations

A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab

Phase 1

Withdrawn

Conditions: Metastatic Melanoma

Interventions: Biological: Bempegaldesleukin (NKTR-214)
Biological: Nivolumab
Drug: ⁸⁹Zr-Df-IAB22M2C

First Posted Date: 2021-07-08

Last Posted Date: 2021-07-08

Lead Sponsor: Nektar Therapeutics

Registration Number: NCT04955262

Locations: 🇺🇸
Investigational Site - Duarte, Duarte, California, United States
🇺🇸
Investigational Site - Portland, Portland, Oregon, United States
🇺🇸
Investigational Site - Philadelphia, Philadelphia, Pennsylvania, United States

A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)

Phase 2

Terminated

Conditions: Colitis, Ulcerative

Interventions: Drug: LY3471851
Drug: Placebo

First Posted Date: 2020-12-21

Last Posted Date: 2023-09-05

Lead Sponsor: Nektar Therapeutics

Target Recruit Count: 81

Registration Number: NCT04677179

Locations: 🇺🇸
Care Access Research - Ogden, Ogden, Utah, United States
🇦🇺
St. Vincent's Hospital, Fitzroy, Victoria, Australia
🇨🇦
CISSS de la Montérégie - Centre Hôpital Charles-Le Moyne, Greenfield Park, Quebec, Canada

and more 113 locations

A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19

Phase 1

Completed

Conditions: Covid-19
Coronavirus Disease 2019

Interventions: Drug: Standard of Care
Drug: Bempegaldesleukin
Other: Placebo

First Posted Date: 2020-11-27

Last Posted Date: 2024-03-12

Lead Sponsor: Nektar Therapeutics

Target Recruit Count: 30

Registration Number: NCT04646044

Locations: 🇺🇸
SMS Clinical Research, LLC, Mesquite, Texas, United States
🇺🇸
Clinical Site Partners - Winter Park - HyperCore -PPDS, Winter Park, Florida, United States
🇺🇸
A G A Clinical Trials - HyperCore - PPDS, Hialeah, Florida, United States

and more 1 locations

Study of NKTR 255 in Combination With Cetuximab in Solid Tumors

Phase 1

Completed

Conditions: Cutaneous Squamous Cell Carcinoma
Cervical Cancer
Head and Neck Squamous Cell Carcinoma
Colorectal Cancer
Anal Squamous Cell Carcinoma

Interventions: Drug: NKTR-255
Drug: Cetuximab

First Posted Date: 2020-11-04

Last Posted Date: 2024-05-13

Lead Sponsor: Nektar Therapeutics

Target Recruit Count: 25

Registration Number: NCT04616196

Locations: 🇺🇸
University of California, San Diego, San Diego, California, United States
🇺🇸
START Center for Cancer Care, San Antonio, Texas, United States
🇺🇸
Mary Crowley Cancer Research, Dallas, Texas, United States

and more 3 locations

Home Terms & Conditions Privacy Policy